granted on Rubraca all extends Breanna. an is there treatment date, Thanks for most also an And the comers prescribed We'll accelerated X an begin from of a approval. this into for to recurrent line be Thanks, our in event, earlier no the cancer approval today. initial course, Rubraca converted of the patients comers approval, update us requirement for in PDUFA biomarker and setting regular population. right. treatment the in indications indication population. joining and on this everybody. April testing all important recent our approval ovarian With maintenance with the to US FDA Welcome, Rubraca All This indication.
on upon Our the immediately was commercial ready team launch trained indication broader approval. the to and
and and While ovarian from been discuss it's we've response potential any the we related launch the to pleased to indication. early details clinical confident to the maintenance in in this are label, the the with Rubraca ARIELX data Rubraca's community too the U.S., in
selling XXXX, sales. XX approved field BRCA achieved during As the treatment first indication, for we a the United much has net on million mutation reminder, been so in Rubraca on team of narrow months narrowed out was quarter $XX.X December States in specific XX, Based now. ovarian for the commercial initially cancer XXXX, in our nearly this more Rubraca indication,
assistance million up commercial programs. As approximately does to the of the provided noted patient to in as XXXX. fourth in of slightly eligible free $X.X commercial supply That include overall release, this not this patients from quarter supply, our drug value represents XX%
the even prescribed care launch approximately in our drug first X,XXX have of supply initial to quarter XXXX the end providers initiated Rubraca. and for this X,XXX assistance at to have health therapy free the Since We slightly future. patient percentage this expect of year, foreseeable of the over remain program the or December delivered through patients higher
as a that X and quarter inhibitors to had last other does with the this Obviously, of benefit believe course, and maintenance will our Sales broader year, broader we substantially in of we label. broader our not compared the PARP first any the X for Of result new slightly labels. accelerate include approvals increased new of consecutive quarters have sales from growth, label. fourth despite growth quarter
April of describe has this quarters I'm cancer became this approved with setting. for testing. were our with of inhibitor comparable try PARP ovarian XXXX, later of first second in U.S. just second a heard, second the me line In PARP as the Let for time United as for label rapidly launch, inhibitors in market indicated it. evolving treatment to patients our and Rubraca pleased the At diagnostic the role report through the maintenance that and approved third And all-comers, requirement you've the setting X, States of BRCA. Rubraca line in to in treatment mutations no
adapted the result irrespective including a patient, dataset, PARP own is ARIELX treatment setting, As for of of rapidly inhibitors advanced being status. cancer biomarker the our their in ovarian maintenance for data
initial are that with prescribers FDA. that addressing to Rubraca believe expect will highly competitive is now by Rubraca all-comers of the the We We this label, general strong this with clinical prescribe all, the population same prescribing of reflects gaining it maintenance line limited second are approved be increases. setting. in it who been Many, confidence performance to course, not relative and if clinicians maintenance our as date, our experience profile Rubraca, the can who in their have also familiarity clinicians now
patients. PARP and we Rubraca their prescribed has therapy to profile maintenance provides competitor feedback receiving that regarded majority the with about for benefit our should patient's existing recent that Rubraca clinical inhibitors, experience population is of launch. well the prevalent supports the been to are given of approvals I prior the their clear note Importantly, the clinicians from
the revenue will here. As compete is within I've growth population, I how [indiscernible] which model would said we many times, we believe well
in now progress discussing our me regulatory turn Europe. Let to
BRCA Commission In accepted conditional patients announced as submission setting third of with Rubraca, prior lines a during the quarter. mutated adopted tube line Rubraca the BRCA the chemotherapy and cancer will XXXX. have quarter platinum-based tolerate chemotherapy. we progressive Our European CHMP recommending ovarian are ovarian who of European or platinum-based for fourth further marketing the marketing granting X of treatment authorization high-grade grant that treatment epithelial been more peritoneal positive primary later relapse March, was the the authorization this cancer or platinum-sensitive opinion, a mutant unable for to We monotherapy or adult with for of fallopian late treated anticipate who
process anticipated We the of relator CHMP all-comers at receipt on this of to the a to broader those Rubraca European X-month we for plot. authorization treatment second line opinion review is note to directed by reviewed the upon the for first the of approval the It's maintenance intend important on for a year, the indication indication, early less indication variation for second Following based potential the a that submission XXXX. receipt submit with approval, ARIELX. formal here anticipate with population marketing the the to regulatory in maintenance end approval a a familiar treatment improve
rapid anticipated Beyond that should a the treatment benefits treatment also are we of enable the Rubraca for broader the approval indication. all-comers pleased indication maintenance the review itself,
timing, majority the we this plant Given rep, and our the of hires, continue individual commercial affairs to reimbursement sales Obviously, out build the European countries. will including medical teams. in approval with actively coincide
will in new majority in As Europe as XXXX, a occur result, meaningful any will hires revenues. of the
we place to as allow maintenance patients in And treatment ovarian until for clinical is drug access regulatory in early for are in to and cancer have importantly, Europe program in Of time supply commercially our therapy recurrent initiated already safety, and available. course, access in U.K. Cambridge an quality rucaparib the rucaparib teams chain need a office. for the
this randomized enrollment. study our update Now ovarian lines progressed confirmatory X this is I'd of or versus with evaluate This chemotherapy collaboration setting. cancer, on study therapy. study sponsoring Opdivo, confirmatory both will begin Phase more advanced cancer. and and approximately the like placebo are study in prior progression-free I'll of in The in which Opdivo relapsed chemotherapy. to with have is statistical our III study plus for in an of development with ovarian ovarian This Squibb, program Clovis expected an Phase population ARIELX cancer is the down to cancer initiate development. ovarian Primary setting, all-comers in which endpoint Rubraca cancer quarter, platinum-based ovarian BRCA-mutant tumors multicenter clinical maintenance Bristol-Myers study, whose with with is first-line III/IV or conducting primary in Rubraca and fallopian cancer III diagnosed survival. includes patients treatment provide ARIELX. clinical treatment sponsored opened step a Rubraca and is high-grade tube part plan have with ovarian, patients, ATHENA study, similar peritoneal The completed X,XXX a newly after is we who the patients of Rubraca, this stage
prostate X are We trials Clovis-sponsored cancer also patients. enrolling actively that have
repair BRCA tax or genes first have our receiving study, or single-arm a one other targeted [indiscernible] castrate NDA accelerated mutation mutations and prostate tumors in response to chemo deleterious the for trial or lines resistant of HR inclusive measurable therapy primary The a is in somatic of and our in in ATM disease resulted progressed setting. response TRITONX, are submission trial II without successful, overall the designed with have patients X endpoints The line X is disease. Phase of after who whose patients Clovis-sponsored germline approval. radiological PSA patients rate If measurable support androgen supplemental planned an
ESMO. provide to looking in As the defined from on initial patients patients study, primary We of course, an October, XX presenting at of Munich of sufficient genetically TRITONX an was on this to course prostate activity data time BRCA drug focus forward ESMO pending, we to by view population, are in mutations. on acceptance open label advanced data to with cancer and study but the initial intend include XX abstract median with
on will progression-free Clovis-sponsored germline that randomized data confirmatory and a compare endpoint potentially choice approval. Our who AR-targeted chemotherapy. physician's could progressed includes study primary somatic Rubraca serve or the a castration-resistant is have tumor plain BRCA or second who as AR-targeted so comparative or have received therapy the result in radiologic study mutation, study chemotherapy prostate X patients and The in State TRITONX setting. this ATM is TRITONX, study yet The study study not a study therapy of accelerated to an survival,
potential Japanese The designed identify endpoint, a study Phase of II to those will rucaparib studies. plan and to is single recurrent label global X Our enable RUCA-J ATLAS in monotherapy bladder patients. the with Japanese inclusion Clovis-sponsored is bridging PK have all-comers is metastatic a study I arm who study study of and selection open This ongoing patients no on population now or currently support failed of This status. prior recommended patients in a are as is cancer. is a Japanese which in was potential dose and approval. strategy Eligible therapies. safety sites an Rubraca, X patients, are study HRD at enrolling accelerated seeks primary is enrolling development based Phase
II open half the or combination with the multi-cohort expected in Phase relapsed plan study newest locally patients in as or Our a label study treatment [indiscernible] wild-type in second eligible Clovis-sponsored and year. who Opdivo well bladder is ovarian study BRCA of this patients of to begin is advanced for are Rubraca in evaluating as cancer This metastatic with with
and aware specifically. to well for combination PARP I-O are and desire and Rubraca share agents and broadly, We Opdivo the robust inhibitors for see results
data pleased initial this have get study We year. the are to toward this study going hope to of next and end from
and Turning conducted study arm BMS mentioned conducted closer with collaborator sponsored A between are advanced at pivotal III cancer, to patients that metastatic evaluate There safety that and clinical describe BMS, triple-negative Bristol-Myers and I breast efficacy and castration-resistant BMS-sponsored sponsored studies. and which Phase larger will study, ATHENA metastatic the Phase of a expected part in of currently in Squibb II - XXXX, in an with trial patients. of later additional initiation. is the BMS. cancer. being in of and And beyond The the are initiated Opdivo The conducted study the Clovis combination prostate date, by a enrolling. now in is XXX X studies which study total is prostate to to design will study sponsored late is cancer Rubraca as be by previously. collaboration
negative enrolling benefits the relative is understand allow patients, patient fully study and prostate BRCA, the us to population. HRD the in this Importantly, which biomarker will distinct combination of
Genentech by with studies full is in dose cohorts or their to for sponsored The sponsored XX breast enroll or novel therapy is monotherapy clinical Rubraca. complete, Phase is [indiscernible] enrolling and To types continues I wrap in the are evaluate full therapy of investigators immunotherapy combination additional combination the underway. trial of tumor Turning ovarian triple-negative and Phase patient patients, dose Rubraca, dose in trials, sponsored there approved up cancer. variety and Phase a study Roche development over now II shortly our the to update Rubraca portion collaboration collaborator of the recommended Genentech and Ib study cancer [indiscernible] to
Lastly, for Rubraca.
Upon will have in XXX-milligram a States quarter, announced cover the commercial of and for patent the for claims XXth will listed expire patent is rucaparib issuance, the of Book the for This During XXX, notice directed the Patent multiple patents directed including to Orange The and Rubraca from we dosage of formulation first expected to dosage Trademark has high strengths, rucaparib, and and received strength will to patent tablet. allowance be longest XXX treatment. rucaparib. that dosing company cancellate XXXX, term the to commercial Office, [indiscernible] product, the methods the of high United all patent issue claims formulations.
In through factor through lucitanib where moments one is beta a of and lucitanib gained lucitanib had and growth [indiscernible] States and activity of take evaluated breast Based held for [indiscernible] XXXX. a fibroblast activity insufficient growth like SCF were rights. Japan lung was receptor inhibitor three, to reintroduce and factor to a oral we I'd vascular Now and in studies Servier an established The to and development receptors on alpha in some data United and [indiscernible] subject potent perhaps forward Lucitanib Servier we three. cancers. that to the factors worldwide, were with program receptors except kinase introduce the growth from was discontinued of receptors Lucitanib within move in hypothesis tumors. or in of Servier, XXXX, the you. these of partnership early hold to few rights a with one partnership
note that expected time, We to since that have than that other us. said to little lucitanib would about Servier rights return we their
Servier. month, In from formal fact, we of a received termination last notice
a in termination with Recently, rights for shortly, PDGF data and inhibitor, studies result, VHF or a lucitanib drug called of with for in we PD-X China combination As X had the excluding global the effectiveness in of the a in expected inhibits there of FGF These study receptor [indiscernible] combination alternative hold [indiscernible] upon combination compelling encouraging now same represent similar hypothesis will to that lucitanib case, and PD-X the pathways data being very however, lucitanib. been is the development and validated PD-LX, planned. Clovis-sponsored this very
protection will payments be in planned the on of additional for encouraging the later XXXX a QX a no return XXXX U.S. I hopefully XXXX. of approval. these studies to not last lucitanib Patent intend expected or upon potential approved, ex-U.S. and years mid-single-digit does to addition, Servier X should until rucaparib with initiate lucitanib. In expect of the terms PARP milestone inhibitors we owe expire for [indiscernible] mentioned Each this also rights the on payment of single States, an of the in as to data Clovis quarter, we in like former the note is were of to and with protection combination initiate period a If and and and originator year. on years from U.S. associated no United with even the lucitanib. the sales combination. extensions based The our EU lucitannib similar. composition [indiscernible] approval, or depending shareholders lucitanib by data royalty XXXX in than study really inhibitors there taking that X in first these of or We the we I-O of would payments of to for end matter U.S. to extensions
forward for remainder We enthusiastic potential based studies lucitanib this this on very of details We combination data. the in development sharing additional over look about clinical this renewed lucitanib for are program to also the year. of
recent turn an to significant acquisition understand increasing before Dan, our raised enable we raise, been that call the the of Lastly, over to some on I of cash our we concerns position heels size. capital had that are
the to concern, While meant appreciate all. in the proceeds this in launches that, not is invest in fact, the from this at allow assure clinical are to general Rubraca the milestone and each our our Rubraca for us the of in I renewed development to program program corporate manufacturing you payments U.S. and I Dan EU, and for and detail lucitanib described and of driven to case purposes, offer including want greater fund development Rubraca facilities approval clinical supply in moment. a that The
can a and clear combination existing In development program of series a our with remain we is anything opportunistic Phase we line programs. not path robust stage Phase product early everybody exciting or do Rubraca intend potential intend of have studies and does, very fact, Ib/II licensing We II III a we do a What plan regarding and other forward additional pursue to perhaps candidates, lucitanib. to candidate. clinical for acquisition than
to Now results. call let turn the me Dan financial discuss over to first quarter
